Economic analysis of insulin initiation by pharmacists in a Canadian setting

Abstract

Background:

Conducted in Alberta, the RxING study examined the effect of a community pharmacist prescribing intervention on glycemic control in patients with uncontrolled type 2 diabetes mellitus (T2DM) using insulin glargine. The objective of this study was to assess the cost-effectiveness of pharmacists’ prescribing of insulin glargine as an early intervention in uncontrolled patients with T2DM vs usual clinical practice.

Methods:

The IMS CORE diabetes Markov model was used to project long-term clinical outcomes, costs and cost-effectiveness of interventions. The efficacy of insulin glargine, in terms of hemoglobin A1c reduction and hypoglycemia rates, was obtained from the RxING study. Health utility and cost data were found in Canadian publications. The base-case analyses examined the economic and clinical effects of having pharmacists initiate insulin therapy in patients with uncontrolled T2DM in comparison to a physician initiate it up to 3 years later.

Results:

Insulin initiation by pharmacists with uncontrolled T2DM patients is cost-effective. Having pharmacists prescribe insulin 1 year earlier than usual clinical practice resulted in an incremental cost savings of $805 (CDN$) and a gain of 0.048 QALYs per patient. Pharmacists prescribing insulin 2 years earlier resulted in an incremental cost savings of $624 (CDN$) per year and a gain of 0.075 quality-adjusted life-years (QALYs). Prescribing 3 years earlier allowed for a minor increase of $26 and a gain of 0.086 QALYs.

Conclusion:

Earlier initiation of insulin by pharmacists, in uncontrolled T2DM patients, resulted in cost savings and delays in the development of diabetes-related complications, leading to an improved quality of life and increased survival rates.

Get full access to this article

View all access options for this article.

References

Lebovitz

HE.

Insulin secretagogues: old and new. Diabetes Rev 1999;7:139-53.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes. Can J Diabetes 2013;37:S61-8.

Al Hamarneh

Charrois

Lewanczuk

. Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open 2013;3:e003154.

Harris

Kapor

Lank

. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010;56:e418-24.

Shah

Hux

Laupacis

. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005;28:600-6.

Palmer

Roze

Valentine

. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(suppl 1):S5-26.

Canadian Agency for Drugs and Technologies in Health. CADTH therapeutic review: economic evaluation: third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and sulfonylurea combination therapy. August 2010. Available: https://www.cadth.ca/sites/default/files/pdf/Diabetes_TR_Economic_Evaluation_Final_e.pdf (accessed Mar 1, 2016).

Cameron

Bennett

HA.

Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009;180:400

World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2106. Available: www.whocc.no/atc_ddd_index/ (accessed Jul. 20, 2014).

10.

Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes: update. CADTH Optimal Use Report 2013. Available: https://www.cadth.ca/sites/default/files/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf (accessed Mar. 1, 2016).

11.

Alberta Health. Interactive drug benefit list. Available: https://idbl.ab.bluecross.ca/idbl/load.do (accessed Aug. 15, 2014).

12.

Harris

Leiter

Yale

. Out-of-pocket costs of managing hyperglycemia and hypoglycemia in patients with type 1 diabetes and insulin-treated type 2 diabetes. Can J Diabetes 2007;31(1):25-33.

13.

Guillermin

Samyshkin

Wright

. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. J Med Econ 2011;14:207-16.

14.

O’Reilly

Hopkins

Blackhouse

. Development of an Ontario Diabetes Economic Model (ODEM) and application to a multidisciplinary primary care diabetes management program. November 2006. Available: www.path-hta.ca/Libraries/Reports/Development_of_an_Ontario_Diabetes_Economic_Model_ODEM_and_Application_to_a_Multidisciplinary_Primary_Care_Diabetes_Management_Program.sflb.ashx (accessed Jul. 23, 2012).

15.

Alberta Health and Wellness. Health costing in Alberta: 2006 annual report. Available: www.assembly.ab.ca/lao/library/egovdocs/2006/alhw/129693_06.pdf (accessed Jul. 23, 2012).

16.

Manns

Lee

Taub

. Cost analysis of ongoing care of patients with end-stage renal disease: what are the important determinants? Edmonton (AB): Alberta Centre for Health Services Utilization Research; 2003.

17.

O’Brien

Patrick

Caro

JJ.

Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3:7.

18.

Ontario Case Costing Initiative. OCCP website. 2010. Available: www.occp.com (accessed Jul. 23, 2012).

19.

Laupacis

Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

CMAJ 2002;166:44-7.

20.

Gerstein

Yale

J-F

Harris

. A randomized trial of adding insulin glargine vs avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736-42.